指南与共识乳腺癌

基于临床-公共卫生效用的乳腺癌胚系多基因面板检测在主流肿瘤学中的应用:ESMO精准肿瘤学工作组推荐

Breast cancer germline multigene panel testing in mainstream oncology based on clinical-public health utility: ESMO Precision Oncology Working Group recommendations.
指南 / 共识 · Ann Oncol · 2025-06-15

ESMO精准肿瘤学工作组建立国际专家组,制定框架评估乳腺癌易感基因是否纳入乳腺癌多基因面板检测(BC-MGPT)用于主流检测,并按对癌症相关死亡率的影响评分。专家组同意基于净临床-公共卫生效用构建BC-MGPT,判定BRCA1、BRCA2、PALB2、RAD51C、RAD51D和TP53(用于<40岁确诊乳腺癌)为高或中等影响,可能增加BRIP1;CHEK2和ATM证据不足;强烈推荐不纳入STK11、PTEN、NF1和CDH1等综合征基因。

要点

  • BC-MGPT应基于净临床-公共卫生效用构建,以对癌症相关死亡率的影响量化。
  • 高或中等影响基因:BRCA1、BRCA2、PALB2、RAD51C、RAD51D和TP53(用于<40岁确诊乳腺癌)。
  • 强烈推荐不纳入STK11、PTEN、NF1和CDH1等综合征基因。

核心结论

  • 随着乳腺癌胚系检测扩大及家系级联检测,检出的胚系致病性变异携带者数量和性质取决于 upfront BC-MGPT 所含基因。
  • 对携带者数十年多器官监测和降低风险手术的潜在危害、机会和经济成本,应由癌症相关死亡率(或健康相关生活质量)有意义的改善的强证据来证明合理性。

研究设计与样本

  • ESMO精准肿瘤学工作组建立乳腺癌胚系遗传学国际专家组(EWG)。
  • EWG首先建立标准框架,用于评估每个乳腺癌易感基因(BCSG)纳入乳腺癌多基因面板检测(BC-MGPT)进行乳腺癌病例普遍主流检测的潜在资格。
  • EWG对BCSG在以下方面的影响评分:(i)乳腺癌风险估计,(ii)临床可操作性,(iii)癌症相关死亡率。

主要发现

  • 专家组同意基于净临床-公共卫生效用构建BC-MGPT,以对癌症相关死亡率的影响可能性量化。
  • 判定为高或中等影响的六个BCSG:BRCA1、BRCA2、PALB2、RAD51C、RAD51D和TP53(用于<40岁确诊乳腺癌),可能增加BRIP1。
  • CHEK2和ATM可能对乳腺癌风险估计有信息价值,但判定为改善癌症相关死亡率的证据不足。
  • EWG强烈推荐不纳入STK11、PTEN、NF1和CDH1等综合征基因。

关键数值与推荐

  • 高或中等影响基因:BRCA1、BRCA2、PALB2、RAD51C、RAD51D和TP53(用于<40岁确诊乳腺癌),可能增加BRIP1。
  • CHEK2和ATM判定为改善癌症相关死亡率的证据不足。
  • 强烈推荐不纳入STK11、PTEN、NF1和CDH1等综合征基因。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: With widening therapeutic indications, germline genetic testing is offered to an increasing proportion of patients with breast cancer (BC) via mainstream oncology services. However, the gene set tested varies widely from just BRCA1/BRCA2 through to 'pan-cancer' panels of nearly 100 genes. If a germline pathogenic variant (GPV) is detected, the BC proband and other family GPV-carriers may be offered interventions such as risk-reducing surgery and intensive surveillance over decades for the various cancers linked to that gene. METHODS: The European Society for Medical Oncology (ESMO) Precision Oncology Working Group established an international expert working group (EWG) in BC germline genetics. This EWG firstly established a framework of criteria by which to evaluate each breast cancer susceptibility gene (BCSG) for potential inclusion on a breast cancer multigene panel test (BC-MGPT) for universal mainstream testing for BC cases. Next, the EWG scored BCSGs for impact regarding (i) BC risk estimation, (ii) clinical actionability and (iii) cancer-related mortality. RESULTS: The group agreed that they would constitute a BC-MGPT based on net clinical-public health utility, as quantified by likelihood of impact on cancer-related mortality. Judged as of high or moderate impact on this basis were six BCSGs: BRCA1, BRCA2, PALB2, RAD51C, RAD51D and TP53 (for BC diagnosed <40 years of age), with possible addition of BRIP1. While potentially informative for BC risk estimation, CHEK2 and ATM were judged to offer insufficient evidence for improving cancer-related mortality. The EWG recommended strongly against inclusion of 'syndromic' genes such as STK11, PTEN, NF1 and CDH1. CONCLUSIONS: With expanded germline testing in patients with BC (and cascade testing into families), the number and nature of resultant GPV-carriers identified will be dictated by the genes included on the upfront BC-MGPT. The potential harms, opportunity and economic costs of decades of surveillance of multiple organs and risk-reducing surgeries for GPV-carriers should be justified by strong evidence of meaningful improvement in cancer-related mortality (or health-related quality of life).

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Turnbull C, Achatz MI, Balmaña J, et al. Breast cancer germline multigene panel testing in mainstream oncology based on clinical-public health utility: ESMO Precision Oncology Working Group recommendations. Ann Oncol. 2025. PMID: 40523834. doi:10.1016/j.annonc.2025.04.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。